Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

CRB Bio II and ADE Capital Sodical Commits €3M Seed Investment Round

Published: Monday, July 08, 2013
Last Updated: Monday, July 08, 2013
Bookmark and Share
Raman Health Technologies develops a new non invasive diagnostic technology platform for multiple diseases based on Raman laser spectroscopy.

CRB Bio II and ADE Capital Sodical have committed a €3M seed investment round in Raman Health Technologies, a new start up company developing a new non invasive diagnostic technology platform based on Raman laser and Infrared spectroscopy. Its first indication will be for the early diagnosis of Alzheimer disease in a blood sample.

Raman Health, based at the Boecillo Technology Park, is a spin-off of the University of Valladolid Fernando Rull, Professor of Crystallography and Mineralogy of the University of Valladolid is one of the key persons in this project.

This financing round will allow the company to achieve its strategic objectives, namely the establishment of a new expanded lab facility to foster the development of the methodology for the detection of spectroscopic biomarkers and the development of a robust diagnostic platform.

Laser to detect Alzheimer
The platform being developed by Raman Health Technologies will be used for the diagnosis of different diseases in a blood sample.

In the case of Alzheimer disease, it avoids the need of invasive techniques, like the lumbar punction to obtain cerebrospinal fluid and will provide a significant improvement in costs and logistics compared to Imaging Technologies (NMR or PET).

Additionally, based on its capability to identify different biological substances, the spectroscopy of Raman Health Technologies can provide simultaneously information of several biomarkers with just one spectroscopic reading.

When compared to other diagnostic technologies, Raman-Laser based spectroscopy is faster, less invasive and cheaper. Additionally no reagents are needed. Raman Health Technologies can change the diagnosis of complex diseases like Alzheimer.

CRB Bio II third investment
This transaction is the third investment made by CRB Bio II, one of the largest specialized Life Science Funds in Spain, after those made in Oncovision and Amadix, for a total aggregated investment in excess of €3,5M.

“This last investment underscores our commitment to invest in disruptive technologies at early stage of development in life sciences. In the case of Raman Health Technologies, this is a very cost-effective technology, with a terrific potential and multiple application areas.” says Pablo Cabello, CSO of CRB Inverbío.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos